Company Profile
Emyria delivers and develops of treatments for mental health and select neurological conditions in Australia. Its operations are structured into Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression.
It also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnership with the University of Western Australia to support the expand Emyria's MDMA analogue drug development program. Incorporated in 2018 and headquartered in Leederville, Australia, Emyria was formerly known as Emerald Clinics Limited before rebranding in September 2020.